NSE: MAXHEALTH | BSE: 543220

Expensive Performer

Download real time

1050.50 -12.10 (-1.14%)

1.6M NSE+BSE Volume

NSE 05 Jan, 2026 3:31 PM (IST)

102,189.4

Market Cap

Market Leader

Beta 1Year

High Volatility

Max Healthcare Institute Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MAXHEALTH, BSE:543220 Max Healthcare Institute Ltd.

Search Inside the pdf :

Max Healthcare Institute Ltd.

18 Nov 2025

1050.50

-1.14%

Result Update:Max Healthcare

Buy: Max Healthcare Institute Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock with a TP of Rs 1,425/share, implying an upside potential of 27% from the CMP.

Max Healthcare Institute Ltd. is trading below all available SMAs

Max Healthcare Institute Ltd.

17 Nov 2025

1050.50

-1.14%

Steady delivery; bed capacity expansion continues

Buy: Max Healthcare Institute Ltd.

Target

Motilal Oswal

Max Healthcare (MAXH) reported in-line revenue and slightly better-thanexpected EBITDA in 2QFY26. The overall performance was robust, with consistent 20%+ YoY revenue growth and better or in-line EBITDA YoY growth.

Max Healthcare Insti.. has an average target of 1348.00 from 5 brokers.

Max Healthcare Institute Ltd.

02 Sep 2025

1050.50

-1.14%

MAX HEALTHCARE INSTITUTE LIMITED

Hold: Max Healthcare Institute Ltd.

Target

Geojit BNP Paribas

The company's impressive Q1FY26 performance, which saw robust revenue growth, was fuelled by higher occupancy rates and ARPOB. This in turn led to an expansion in margins and profitability. The company's ambitious expansion plan to double its capacity over the next 4-5 years remain on track, with plans to add approximately 1,000 brownfield and 500 greenfield beds. The healthy growth and occupancy trends observed in the existing and recently acquired units further reinforce the positive outlook. The stock is trading at elevated valuations therefore we downgrade...

Number of FII/FPI investors decreased from 1145 to 1089 in Sep 2025 qtr

Max Healthcare Institute Ltd.

18 Aug 2025

1050.50

-1.14%

Result Update:Max Healthcare

Buy: Max Healthcare Institute Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock with a TP of Rs 1,450/share, implying an upside potential of 19% from the CMP.

Max Healthcare Institute Ltd. is trading below all available SMAs

Max Healthcare Institute Ltd.

14 Aug 2025

1050.50

-1.14%

Max Healthcare Institute (MAXHEALT IN) Q1FY26 Result Update ...

Buy: Max Healthcare Institute Ltd.

Target

Prabhudas Lilladhar

Max Healthcare Institute (MAXHEALT) reported healthy EBITDA growth of 23% YoY to Rs 6.14bn; in line with our estimates. The company showed phenomenal growth with ~19% EBITDA CAGR over FY22-25. We expect pick-up in the growth momentum given 1) strong expansion plans (+3700 additional beds over FY25-28E), 2) improving payor mix and 3) Bolt on acquisitions like recently added in Lucknow, Nagpur and Noida. Operational efficiency has also been commendable, especially in competitive markets like NCR. Our FY26E/27E...

Max Healthcare Insti.. has an average target of 1348.00 from 5 brokers.

Max Healthcare Institute Ltd.

22 May 2025

1050.50

-1.14%

Max Healthcare Institute (MAXHEALT IN) Q4FY25 Result Update ...

Buy: Max Healthcare Institute Ltd.

Target

Prabhudas Lilladhar

Dwarka unit achieved break-even vs loss of Rs50mn in Q3. YoY to Rs 6.32bn; in line with our estimates. The company showed phenomenal additions. We expect pick-up in the growth momentum given 1) strong expansion plans (+3500 additional beds over FY24-27E), 2) improving payor mix and 3) Bolt on acquisitions like recently added in Lucknow, Nagpur and...